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Abstract
Background: Estimates of the burden of maternal morbidity are patchy.
Objective: To conduct a systematic review of systematic reviews of maternal conditions 
to: (1) make available the most up- to- date frequency estimates; (2) identify which condi-
tions do not have reliable estimates; and (3) scrutinize the quality of the available reviews.
Search strategy: We searched Embase, MEDLINE, and CINAHL, combining terms for 
pregnancy, frequency (e.g. prevalence, incidence), publication type, and specific terms 
for each of 121 conditions.
Selection criteria: We included peer- reviewed systematic reviews aiming to estimate 
the frequency of at least one of the conditions in WHO’s list of maternal morbidities, 
with estimates from at least two countries.
Data collection and analysis: We present the frequency estimates with their uncer-
tainty bounds by condition, region, and pregnancy/postpartum period. We also assess 
and present information on the quality of the systematic reviews.
Main results: Out of 11 930 found, 48 reviews were selected and one more was added. 
From 49 reviews we extracted 34 direct and 60 indirect frequency estimates covering 
35 conditions. No review was available for 71% of the conditions on the WHO list. The 
extracted estimates show substantial maternal morbidity, spanning the time before 
and beyond childbirth. There were several gaps in the quality of the reviews. Notably, 
one- third of the estimates were based only on facility- based studies.
Conclusions: Good- quality systematic reviews are needed for several conditions, as a 
research priority.
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1  | INTRODUCTION
The Global Burden of Disease (GBD) study group estimated that 
in 2013 alone, maternal conditions contributed to 18 027 800 
disability- adjusted life years, including morbidity from hemorrhage, 
infection, hypertension, abortion complications, obstructed labor, late 
and indirect maternal deaths, and those deaths aggravated by HIV.1 A 
recent publication suggested that the five main direct obstetric causes 
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of morbidity resulted in 27 million morbid episodes in 2015.2 These 
sources, however, underestimate the true burden of disease attrib-
utable to pregnancy- related conditions as they include only a few 
maternal conditions.3 They ignore common conditions, such as post-
partum depression,3 and mild but prevalent conditions, such as urinary 
incontinence that affects over one- third of the pregnant population in 
Europe alone.4
The WHO recently published a comprehensive list of maternal 
morbidities, comprising 121 direct and indirect conditions.5 This list 
provides an important framework to understand what conditions con-
stitute maternal morbidity, although the extent to which each of the 
listed morbidities contributes to the total burden remains unclear.3 
Addressing this gap in our knowledge is necessary to better prioritize 
conditions for intervention. Furthermore, identifying the conditions 
that we know the least about is also important so they can be included 
in the future research agenda.2
The aim of this systematic review is to identify existing systematic 
reviews quantifying the burden of each of the conditions identified 
in WHO’s list of maternal morbidities. Compiling this information will 
enable us to: (1) make available the most up- to- date frequency (e.g. 
prevalence, incidence) estimates on each maternal condition; (2) iden-
tify which conditions lack reliable estimates; and (3) discuss the quality 
of the systematic reviews and the reliability of the available estimates.
2  | MATERIALS AND METHODS
2.1 | Search strategy
We conducted a systematic search in Embase, MEDLINE, and the 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
using a combination of free text terms and Medical Subject Headings 
(MeSH terms). We combined terms for the following domains: 
pregnancy (e.g. maternal, antenatal), frequency of the disease (e.g. 
prevalence, incidence), publication type (e.g. systematic review, meta- 
analysis), and specific terms for each of the 121 conditions described 
in the WHO maternal morbidity list by Chou et al.5 The search strat-
egy was prepared by AL, CC, and GG, with input from VF, SW, and an 
experienced librarian. The complete strategy is provided in Appendix 
S1. The search was restricted to humans and there were no language 
restrictions. The search was last run on July 23, 2016. In addition, we 
included further relevant systematic reviews known to the authors 
of this paper but not identified by the search, and we searched the 
reference lists of eligible studies. We used the MOOSE guidelines for 
conducting systematic reviews of observational studies to carry out 
and report on this review.6
2.2 | Inclusion and exclusion criteria for selection of 
systematic reviews
We included peer- reviewed systematic reviews that aimed to esti-
mate the frequency of at least one of the maternal conditions listed in 
Chou et al.5 and which included estimates from at least two countries. 
The latter was a way to ensure we included estimates representing a 
region rather than a specific country. We included systematic reviews 
that included at least one paper published in or after 2006, as an 
attempt to provide recent estimates.
We excluded papers that: (1) did not mention frequency of the 
outcome among pregnant women in the abstract; (2) only reviewed 
studies for certain subgroups (e.g. rural women, or women with a spe-
cific health condition, women giving birth to twins, or women with a 
previous cesarean delivery); (3) focused only on risk factors or con-
sequences of a certain maternal condition; (4) were not systematic 
reviews; (5) primarily included interventions for or investigated the 
effect of a single individual characteristic of the relevant maternal 
conditions; (6) were not possible to access in full; and (7) provided 
insufficient information on their inclusion and exclusion criteria in the 
text and the authors did not provide this information after we had 
attempted to contact them twice.
2.3 | Data extraction
Data extraction from eligible reviews was carried out at two levels: 
(1) information on the overall paper; and (2) the specific frequency 
estimate. We did not extract information from the primary studies 
included in the eligible systematic reviews. For the study selection of 
the systematic reviews, one author (AL) screened titles and abstracts, 
and 10% of these were also screened by GG.
During the first level of data extraction, either AL, GG, or CC 
extracted data from eligible reviews such as the region reviewed, 
the databases searched, and the inclusion criteria applied for study 
selection. We also extracted detailed information on the quality of the 
systematic reviews. This was performed by AL with double extraction 
of 50% of the reviews (by GG). To assess the quality, we adapted the 
quality assessment tool for assessing systematic reviews proposed 
by Mann et al.,7 which is a modified version of the Overview Quality 
Assessment Questionnaire (OQAQ). Our adaptations included a ques-
tion on whether authors clearly specified the source of the data—
whether hospital, population, or unknown—and whether the search 
strategy was clearly laid out. The details on the modified OQAQ tool 
we used (which included 13 criteria) and the way we scored against 
it are available in Appendix S2. We did not provide numerical sum-
mary quality scores for each eligible review because these could mask 
the relative importance of the different quality indicators. Instead, we 
used a traffic light system, and we calculated the overall proportion of 
articles scoring a specific color (e.g. green) for each question.
For the second level of data extraction, either GG or AL extracted 
the frequency estimates together with information on whether these 
were population- or facility- based, the denominator for each, the 
countries they represented, the type of estimate (i.e. incidence or 
prevalence), and the diagnostic tools used for case ascertainment. 
Estimates were classified as population based if: (1) authors clearly 
said they were population based, or (2) the sample was recruited from 
facilities in countries where virtually all deliveries happen in facilities. 
For 50% of the papers included, we carried out double extraction of 
the frequency estimates and their details. Any discrepancies were 
resolved through discussion.
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To select “the best” estimates to extract from systematic reviews 
where several frequency estimates were presented, we established 
the following rules that were applied in hierarchical order:
1. Select population-based estimates over (a) facility-based esti-
mates, or (b) estimates combining both facility- and popula-
tion-based estimates.
2. When both pooled estimates (i.e. a weighted average) and the 
range of estimates from individual studies were provided, extract 
the pooled estimate.
3. Select estimates covering the widest geographical area.
4. Select the most recent estimates, in terms of data capture period.
For example, if a review reported a frequency estimate based on 
community- based studies and a separate estimate for facility- based 
studies, then we only extracted the estimate based on the community- 
based studies. If a study reported weighted means based only on facility- 
based studies separately for West Africa and for the whole of the African 
continent, then we selected only the estimate for Africa.
Estimates from systematic reviews where only a single study was 
identified are equivalent to reporting estimates from a single primary 
study; therefore, for the purposes of reporting estimates of maternal 
morbidity, we did not include estimates from such systematic reviews. 
For any reviews that were eligible based on our inclusion and exclusion 
criteria, but from which we could not extract a frequency estimate, we 
have included the paper in the main description but we do not report 
an estimate from it.
2.4 | Analysis
We transformed all estimates into percentages for presentation and 
comparison. For a particular review and each condition reported on, 
we present the frequency and the type of estimate (prevalence or 
incidence), the uncertainty range, region, pregnancy period, diag-
nostic tools, and data source (facility- vs population- based). We 
report the region (or group of countries) for each estimate based 
on the countries covered by the primary studies included in the sys-
tematic review, which underpin each estimate. For those conditions 
reported by multiple eligible systematic reviews, we present esti-
mates from each of those reviews. If those reviews reporting on the 
same condition included some of the same primary studies, we did 
not choose between the reviews because each review had distinct 
inclusion/exclusion criteria; for example, some reviews focused on 
certain countries or study designs. If a systematic review reported 
on multiple conditions of interest, we extracted estimates for each 
of these conditions.
3  | RESULTS
We identified 11 930 results from searches across Embase, MEDLINE, 
and CINAHL, of which 3481 were duplicates and 8302 were unrelated 
to the topic of interest after screening the title and abstract (Fig. 1). A 
total of 150 papers were selected for full- text review, of which three 
were added to the search results based on our previous knowledge. 
Full- text review led to the exclusion of 102 papers for the reasons 
stated in Figure 1, including four articles that were excluded because 
they only reported composite outcomes, aggregating the frequency 
of multiple conditions in the WHO list.8–11 We selected 48 eligible 
systematic reviews, and from searching their references we found one 
more. From these 49 eligible reviews, we extracted 34 direct and 60 
indirect frequency estimates covering 35 conditions. The full list of 
included papers is provided in Appendix S3.
3.1 | Availability of systematic reviews
We found that for 71% of conditions in the WHO list by Chou et al.5 
there was no systematic review available (Appendix S3). The sys-
tematic reviews we found covered a substantial proportion (36%) of 
direct and coincidental maternal conditions, as well as several mental 
disorders (63%), and maternal infectious and parasitic diseases (46%). 
Under the direct morbidity umbrella, our search did not yield any sys-
tematic review for three categories: (1) pregnancy- related infection, 
such as puerperal sepsis or mastitis; (2) cardiovascular obstetric com-
plications such as peripartum cardiomyopathy; and (3) complications 
related to anesthesia.
In addition, we did not find any eligible systematic reviews for 
nine indirect morbidity categories listed by Chou et al.,5 as outlined 
in full in Appendix S3. For example, none were found in the category 
called “Other maternal diseases classifiable elsewhere but complicat-
ing pregnancy, childbirth and the puerperium,” which includes ane-
mia, and we also found none under “Diseases of the musculoskeletal 
system and connective tissue,” including back pain. A systematic 
review on anemia was not considered eligible because it aimed to 
review primary studies investigating the risk factors for anemia, 
therefore excluding studies that investigated the frequency of ane-
mia but did not report on effect- size estimates of risk factors.12
Some conditions had multiple available systematic reviews. The 
highest number was identified for gestational diabetes (eight system-
atic reviews),13–20 followed by infectious hepatitis, intimate partner 
violence, and postpartum depression, with four systematic reviews 
each. Although two systematic reviews were eligible and included, 
we have not reported frequency estimates for these because either 
the estimates were based on only one study per condition,21 or they 
reviewed a variety of conditions and denominators that were difficult 
to combine to present summary estimates here22; details are provided 
in Appendix S3.
3.2 | Characteristics of available systematic reviews
Details of the 94 frequency estimates extracted, including the denom-
inator and the geographical area for each are presented by pregnancy 
period and by type of estimate in Table 1 (direct maternal morbidities) 
and Table 2 (indirect maternal morbidities). The systematic reviews 
used several types of prevalence (n=77) or incidence (n=17) estimates, 
including ranges, weighted means, crude means, and medians. The 
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denominator varied according to the condition and the authors, and 
generally included births, pregnancies, deliveries, women of reproduc-
tive age (for fistula), and person- years at risk (for HIV). Further details 
about the estimates are in Tables 1 and 2, and additional details are 
provided in Appendix S4.
The systematic reviews covered different geographical and eco-
nomic areas, e.g. the world, high- income countries (HICs), low- and 
middle- income countries (LMICs), or specific regions (Africa, Asia, 
Europe, etc.). Of the estimates we extracted, 17 (18%) were based on 
only two countries or it was not clear from the paper how many coun-
tries were included. Among the frequency estimates that included 
worldwide studies, the median number of countries contributing data 
was 10 (interquartile range, 7.5–20.5). Sub- Saharan Africa was the 
world region with the highest number of specifically dedicated sys-
tematic reviews (n=9).
Tables 1 and 2 describe the outcome assessment method behind 
each estimate. Information on assessment method at the estimate 
level was often scarce and poorly described. For direct morbidity 
estimates, the information on the assessment method underlying the 
estimates was unclear in five systematic reviews.17,23–26 In addition, 
some studies used assessment methods that are prone to bias. To take 
the example of gestational diabetes, Schneider et al.,18 and Hunt and 
Schuller 15 included primary studies that used self- report. Zhu and 
Zhang,20 on the other hand, reported clearly on diagnostic criteria at 
the estimate level.
3.3 | Quality of systematic reviews
There was much variation in the quality of the 49 systematic reviews, 
including some examples of excellent methodology and reporting.27–29 
Some aspects of quality were often found to be particularly poor, includ-
ing insufficient reporting and methodological gaps (Fig. 2). For example, 
only 19 (39%) of the systematic reviews explicitly reported their lan-
guage exclusions and the inclusion of grey literature, and only 21 (43%) 
provided a detailed description of the primary studies. Furthermore, for 
16 (33%) of the reviews we did not have sufficient details on the data 
extraction process (e.g. use of independent extraction).
Information on data collection and sources was also lacking in 
many cases: for 19 (56%) of the direct morbidity estimates and 18 
(30%) of the indirect estimates there was insufficient information 
to assess whether the data were from population- or facility- based 
sources. Overall, 32 (34%) of the estimates extracted included data 
from facility- based studies. Facility- based studies vary in terms of 
their representativeness. For example, when reviewing studies of the 
prevalence of malaria, Chico et al.27 included women attending ante-
natal care clinics, a service that currently most African women attend 
F IGURE  1 Study selection for inclusion in the systematic review.
102 articles excluded: 
16 latest included study 
published before 2006 
or no information on 
dates
6 specific subgroups of 
population 
1 review of reviews 
41 no frequency of 
outcome among 
pregnant women 
6 no outcome of interest 
17 nonsystematic 
review
2 could not get copy of 
article 
6 only conference 
abstracts
3 authors did not reply 
4 had a composite 
outcome
11930 identified by search 
carried out on July 23, 2016 
(restricted to humans)
3 articles from authors’ 
previous knowledge 
8449 titles and abstracts 
reviewed
147 articles selected for full 
text review 
3481 articles excluded: 
duplication
8302 articles excluded from 
titles/abstract review 
49 articles included
1 article found in 
references of included 
article
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at least once during pregnancy. Nevertheless, as the authors indicate, 
these estimates are only representative of those who attended ante-
natal care, and this paper includes studies from Africa going back at 
least two decades when antenatal care attendance was much lower.
One- third (n=16; 32%) of the systematic reviews did not explicitly 
report whether they performed a quality assessment of their primary 
studies. Even when a quality assessment was conducted, most stud-
ies did not use a standardized tool or did not report which tool they 
used or the results. Publication bias was assessed by only 15% of the 
systematic reviews.
3.4 | Frequency of maternal morbidity along the 
pregnancy–postpartum continuum
As shown in Table 1 and Figure 3, the toll of potentially life- threatening 
direct maternal morbidities is high, with postpartum hemorrhage 
being the most common, estimated at 6.2% based on the review by 
Carroli et al.,30 and at 10.8% based on the more recent review with dif-
ferent population- based criteria by Calvert et al.29 This is followed by 
pre- eclampsia (2.3%),31 severe abortion complications (0.6%),32 and 
eclampsia (0.5%)31 (Table 1). Substantial direct maternal morbidity is 
also present throughout pregnancy with the prevalence of gestational 
diabetes mellitus estimated to be 5.1% in Africa17 and 25.1% in the 
Western Pacific Region (Table 1, Fig. 1).20
The frequency of indirect maternal morbidity is also high (see 
Table 2 and Fig. 4), particularly for mental health and infectious dis-
eases. The prevalence of postpartum depression estimated for LMICs 
ranged from 1.0% to 26.3% according to Norhayati et al.33 and from 
4.9% to 50% according to Parsons et al.34 In Africa, Sawyer et al.35 
estimated the prevalence of pregnancy- related depression at 18.3%. 
Anxiety is another common health problem, with prevalence world-
wide ranging between 4.4% and 39.0%28 during pregnancy, and esti-
mated to affect 8.5% of postpartum women on average.28 The average 
prevalence of anxiety during pregnancy and the postpartum period in 
Africa has been estimated at 14%35 (Table 2).
Regarding infectious diseases,36 the estimated pooled HIV inci-
dence rate in Sub- Saharan Africa is 4.7 per 100 person- years during 
pregnancy and 2.9 per 100 person- years during the postpartum period 
(Table 2). In Sub- Saharan Africa, based on one systematic review,27 the 
reported prevalence of syphilis and chlamydia during pregnancy ranged 
between 2.5% and 2.9% and between 1.9% and 5.2%, respectively. 
Estimates of these conditions across LMICs, as reported in another 
systematic review, range between 0.5% and 8.3% for syphilis and 
between 0.4% and 16.4% for chlamydia (Table 2). Across Sub- Saharan 
Africa, prevalence of malaria during pregnancy (peripheral parasitemia) 
ranges between 29.5% (in Eastern and Southern Africa) and 35.1% (in 
Western and Central Africa).27 Estimates for hepatitis are high, with 
a median of 4.3% of pregnancies diagnosed with seroprevalence of 
hepatitis B serum antigen (HBsAg), and between 2.5%37 and 3.0%38 of 
pregnant women in Africa infected with hepatitis C (Table 2).
Many pregnancies are affected by non- life- threatening conditions. 
Based on evidence predominately from HICs, nausea and vomiting 
have been reported to affect 69.4% of pregnant women23 (Table 1). C
on
di
ti
on
A
ut
ho
r
G
ro
up
 o
f 
co
un
tr
ie
s
Ty
pe
 o
f 
es
ti
m
at
e
U
pp
er
 
lim
it
Lo
w
er
 
lim
it
Po
in
t 
es
ti
m
at
e
N
o.
 o
f 
co
un
tr
ie
s
N
o.
 o
f s
tu
di
es
 
or
 d
at
a 
se
ts
a
P
re
va
le
nc
e 
vs
 in
ci
de
nc
e
P
op
ul
ati
on
 
so
ur
ce
D
en
om
in
at
or
A
ss
es
sm
en
t m
et
ho
d
Pu
lm
on
ar
y 
em
bo
lis
m
Ko
ur
la
ba
, 
20
16
26
W
or
ld
W
ei
gh
te
d 
m
ea
n
0.
06
%
0.
02
%
0.
04
%
7b
7b
In
ci
de
nc
e
N
ot
 c
le
ar
D
el
iv
er
ie
s,
 
pr
eg
na
nt
 a
nd
 
po
st
pa
rt
um
 
w
om
en
N
ot
 c
le
ar
Pu
lm
on
ar
y 
em
bo
lis
m
M
en
g,
 
20
15
57
W
or
ld
W
ei
gh
te
d 
m
ea
n
0.
04
%
0.
02
%
0.
03
%
10
18
In
ci
de
nc
e
N
ot
 c
le
ar
D
el
iv
er
ie
s
C
lin
ic
al
 r
ev
ie
w
 a
nd
 
di
ag
no
sti
c 
te
st
s 
(e
.g
. 
ul
tr
as
ou
nd
)
A
bb
re
vi
ati
on
s:
 A
D
A
, A
m
er
ic
an
 D
ia
be
te
s 
A
ss
oc
ia
ti
on
; E
PD
S,
 E
di
nb
ur
gh
 P
os
tn
at
al
 D
ep
re
ss
io
n 
Sc
al
e;
 E
A
SD
, E
ur
op
ea
n 
Fo
un
da
ti
on
 fo
r 
th
e 
St
ud
y 
of
 D
ia
be
te
s;
 H
IC
s,
 h
ig
h-
 in
co
m
e 
co
un
tr
ie
s;
 IA
D
SP
SG
, I
nt
er
na
ti
on
al
 
A
ss
oc
ia
ti
on
 o
f t
he
 D
ia
be
te
s 
an
d 
Pr
eg
na
nc
y 
St
ud
y 
G
ro
up
s;
 L
M
IC
s,
 lo
w
-  
an
d 
m
id
dl
e-
 in
co
m
e 
co
un
tr
ie
s;
 N
D
D
G
, N
ati
on
al
 D
ia
be
te
s 
D
at
a 
G
ro
up
; A
N
C
, a
nt
en
at
al
 c
ar
e.
a N
um
be
r 
of
 d
at
a 
se
ts
.
b I
t 
w
as
 n
ot
 c
le
ar
 w
he
th
er
 t
he
 d
et
ai
ls
 fo
r 
th
is
 m
at
ch
ed
 t
he
 fr
eq
ue
nc
y 
es
ti
m
at
e 
ex
tr
ac
te
d.
c T
he
y 
de
fin
e 
in
cl
us
io
n 
cr
ite
ria
 f
or
 p
op
ul
ati
on
 a
s 
“s
tu
di
es
 o
n 
in
co
nti
ne
nc
e 
in
 p
op
ul
ati
on
- b
as
ed
 s
am
pl
e 
de
fin
ed
 a
s 
fr
om
 o
ne
 o
r 
m
or
e 
di
st
ric
t 
ho
sp
ita
ls
 o
r 
fr
om
 m
ul
ti
pl
e 
cl
in
ic
s 
co
ve
rin
g 
a 
de
fin
ed
 g
eo
gr
ap
hi
c 
ar
ea
.” 
H
ow
ev
er
, t
w
o 
co
un
tr
ie
s 
co
nt
rib
uti
ng
 t
o 
th
e 
es
ti
m
at
es
 w
er
e 
Tu
rk
ey
 a
nd
 Ir
an
, f
or
 w
hi
ch
 h
os
pi
ta
l r
ec
ru
itm
en
t 
m
ig
ht
 n
ot
 a
lw
ay
s 
be
 e
nti
re
ly
 a
pp
ro
pr
ia
te
.
T
A
B
L
E
 2
 
(C
on
ti
nu
ed
)
     |  33Gon ET AL.
Similarly, based on data from HICs, urinary incontinence has been 
variously estimated to affect 6.7% to 58.1%4 or 26.0% to 75.0%39 of 
women during pregnancy (Table 2).
Obstetric fistula, experienced by under 1% of postpartum women in 
LMICs, is one of the more severe although less prevalent maternal mor-
bidities.32,40,41 Unrepaired fistulae can impact a woman’s health and well- 
being severely for the rest of her lifetime. Similarly, postpartum urinary 
incontinence can persist for a lifetime, and currently affects, on aver-
age, 33.0% of women during the puerperium in HICs according to one 
review,42 or between 3.0% and 31.0% as estimated in another review.4
For some conditions, such as mental health disorders and infec-
tions, the timing of diagnosis may influence the frequency of the 
condition and thus explain differences in estimates between studies; 
this detail was not always reported. In Appendix S5, we summarize the 
case for postpartum depression, for which there are notable differ-
ences between the systematic reviews in how they summarized data 
from longitudinal studies reporting prevalence data for more than one 
time point.
4  | DISCUSSION
We conducted a systematic review of systematic reviews assessing 
the frequency of the 121 WHO maternal morbidities.5 Women suffer 
F IGURE  2 Quality assessment.
First Author Year Q 1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13
Methods Strategy Database  Criteria Bias Validity Extraction Combine report Combine approp. Study descript. Source Public. bias Conclusion
Abalos (31) 2013
Adler (54) 2012
Adler (32) 2013
Banura (61) 2013
Buckley (13) 2012
Calvert (29) 2012
Carroli (30) 2008
Cerruto (4) 2013
Cheung (55) 2011
Chico (27) 2012
Conde-Agudelo (25) 2009
Cowgill (40) 2015
Cresswell (44) 2013
Drake (36) 2014
Einarson (23) 2013
Frati (56) 2013
Goodman (28) 2014
Goodman (68) 2016
Grekin (70) 2014
Han (22) 2013
Hirst (14) 2012
Hunt (15) 2007
Joseph Davey (60) 2016
Kanguru (19) 2014
Kourlaba (26) 2015
Liepe (62) 2013
Maculay (16) 2014
Mendez-Figueroa (21) 2013
Meng (57) 2015
Merrill (58) 2010
Mora (37) 2016
Mwanri (17) 2015
Norhayati (33) 2015
Padua (67) 2010
Parsons (34) 2011
Puccia (63) 2012
Rao (38) 2015
Riou (59) 2016
Roberts (69) 2011
Sangsawang (39) 2012
Sawyer (35) 2010
Schmied (65) 2013
Schneider (18) 2012
Shamu (64) 2011
Sharma (66) 2012
Thom (42) 2010
Villot (24) 2015
Zheng (41) 2009
Zhu (20) 2016
Legend
Yes Partially No No information
Total
46 29 41 40 19 21 18 35 28 21 28 7 43
3 16 3 7 17 8 10 6 6 18 8 NA 5
0 2 5 1 13 4 5 8 5 10 13 42 0
NA 2 NA 1 0 16 16 NA 10 NA NA NA 1
34  |     Gon ET AL.
substantial morbidity during pregnancy, at the time of birth, and in the 
postpartum period. This review also identified important knowledge 
gaps. Surprisingly, no systematic reviews were available for several 
maternal conditions known to be potentially life- threatening and some 
that can lead to long- term disabilities, such as puerperal infection and 
anemia. Another important finding is that the quality of many of the 
49 included systematic reviews was poor. Key areas for improvement 
include the strict inclusion of population- based (rather than facility- 
based) studies and improvement in the reporting of methods in line 
with available guidelines.
The importance of the time around delivery was traditionally 
emphasized in maternal health research as most maternal deaths 
occur in this period. However, our results show that the bur-
den of maternal morbidity is also high before and after the point 
of delivery. Gestational diabetes affects at least 5% of women in 
low- resource settings. Poor mental health is also common during 
pregnancy and in the postpartum period, with depression and 
anxiety the most common conditions. Infectious diseases are also 
frequent, including HIV, malaria, and hepatitis. These data call into 
question the completeness of currently available estimates on the 
overall burden of maternal morbidity (such as the ones provided by 
the GBD study group), as they rely on a limited number of highly 
prevalent maternal conditions, excluding, for example, gestational 
diabetes and anxiety.
Nevertheless, we have limited ability to comment on the fre-
quency of 71% of the conditions listed by Chou et al.5 owing to the 
lack of systematic reviews for them. Furthermore, systematic reviews 
aiming to provide global estimates for a condition included a median 
of only 10 countries, which also casts some doubt on the geographical 
representativeness of currently available estimates of the burden of 
disease. This state of affairs has a number of possible explanations: 
(1) that maternal morbidity is not a research priority; (2) that some 
conditions are challenging to define and measure; and (3) that others 
are very rare and hence unlikely to be covered in a systematic review. 
Information on a wider range of maternal conditions and geographical 
areas should be gathered to produce better estimates.
The differences in prevalence reported for the same conditions, 
such as gestational diabetes and depression, may reflect actual differ-
ences between the populations and the widening inequalities between 
and within regions,2 but they are also likely to be driven by method-
ological differences between the systematic reviews and the primary 
studies they included. Potential drivers include different assessment 
methods, varying definitions of the condition, and differences in the 
study populations and the timing of assessment. For example, the type 
F IGURE  3 Population- based estimates for direct maternal morbidities. Abbreviations: LMICs, low- and middle- income coutries; HICs, high- 
income countries. [Colour figure can be viewed at wileyonlinelibrary.com]
F IGURE  4 Population- based estimates for indirect maternal morbidities. Abbreviations: LMICs, low- and middle- income countries; HICs, 
high- income countries. [Colour figure can be viewed at wileyonlinelibrary.com]
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of assessment method applied can double prevalence estimates for 
a condition such as gestational diabetes.16 Generally, however, esti-
mates for the same condition were relatively consistent; for example, 
estimates for postpartum hemorrhage varied between 6% and 11%, 
and obstetric fistula between 0% and 1.6% in LMICs.
Our results also highlight the existing gaps in the quality of meth-
ods and reporting used in systematic reviews on maternal conditions. 
Crucially, for 56% of the direct and 30% of the indirect estimates, there 
was insufficient information to verify the population or data source. 
Overall, 34% of the estimates extracted included facility- based stud-
ies. As discussed elsewhere, more reliable population- based estimates 
are needed, since mothers who access facilities are likely to be differ-
ent to the ones who do not.43 Lack of facility attendance by women 
during pregnancy, delivery, and the postpartum period could lead to 
underestimation of the frequency of some conditions (e.g. if women 
tend not to seek help for that condition) or overestimation (e.g. if 
women with serious morbidity are more likely to attend a facility). Few 
systematic reviews used a rigorous method to select available data 
from LMICs for inclusion, such as only including hospital- based studies 
if the region in which the study was conducted had at least 95% of 
births attended by a skilled birth attendant.29,44 Other important lim-
itations among the included systematic reviews included the poten-
tial for study selection bias, the inadequate use of quality- assessment 
tools, reporting insufficient detail on the data extraction process, a 
poor description of the primary studies included, and lack of clarity 
about the diagnostic tools used to generate the estimates provided. 
Our findings on the poor quality of systematic reviews resonates 
with those of Sheick et al.,45 who reviewed the quality of systematic 
reviews on maternal medicine in 2007. A decade on, there is still much 
room for improvement.
We propose key steps to improve the quality of systematic reviews 
in the context of maternal morbidity, including the quality of the meth-
ods used to conduct them and the quality of the reporting. Our rec-
ommendations are similar to those proposed for estimating newborn 
morbidity46 and health estimates more broadly.47 These recommen-
dations are addressed to the authors of systematic reviews, primary 
studies, study reviewers, and journal editors. First and foremost, 
researchers should use and report on studies according to standard 
guidelines for the review of observational studies, such as the PRISMA 
and STROBE guidelines.6,48–50 In particular, we encourage the report-
ing of details on the eligible primary studies, including data source, 
sample size, and country.
Other important recommendations include:
1. Explicitly report the data sources (facility- and/or popula-
tion-based) used to generate frequency estimates and for each 
primary study included. The gold standard is to restrict inclusion 
to primary studies that are population-based, or restrict to those 
studies from geographical areas where the majority of women 
attend facility-based services if included studies use facility-based 
recruitment. If this is not possible, pooled estimates should be 
reported separately for studies that used population-based and 
facility-based data collection.
2. Specify what assessment methods were used for each overall esti-
mate presented. It is also good to report different summary esti-
mates by diagnostic criteria. Try and avoid studies that include 
self-reported data except when this is an acceptable way of meas-
uring the condition (e.g. nausea and vomiting). If self-reporting is 
included, discuss the primary studies assessing the validity of the 
self-report (sensitivity and specificity).
3. State the denominator used. Preferably prioritize pregnancies and 
postpartum women with clear definitions of this period (e.g. length 
of time postpartum, etc.).
4. Use appropriate and standardized regional classifications based on 
the final list of primary studies included in the summary estimates 
provided.
5. Provide frequency estimates at different points of the pregnancy–
postpartum continuum, if relevant to the condition of interest.
Whether conditions arising during pregnancy should be quantified 
as incidence or prevalence heavily depends on the condition of interest, 
and the design and aims of a study. Yet many researchers use these terms 
interchangeably in the context of maternal morbidity; this is an issue that 
is beyond the scope of this study. However, we found that reviews of 
certain conditions for which incidence is of interest, such as postpartum 
depression, reported solely on prevalence. In systematic reviews, where 
several primary studies with a variety of designs are included, it can be 
difficult to choose the type of frequency to report. We call for future sys-
tematic reviews to clearly distinguish between incidence and prevalence 
estimates, to disaggregate these data, and to provide more discussion 
on this issue.
Our systematic review of systematic reviews is limited by the lack 
of grading based on diagnostic criteria. We chose not to perform such 
assessment because the primary studies in the included systematic 
reviews spanned across several conditions and decades, during which 
time the appropriateness of diagnostic criteria for different condi-
tions changed. A further limitation is that we did not extract infor-
mation directly from the primary studies identified by the systematic 
reviews—some systematic reviews included the same primary stud-
ies, and we did not always limit the time period for the publication 
of these primary studies—hence our reported frequencies represent 
a wide timescale. Overall, our review is limited by the quality of both 
the included systematic reviews and the primary studies they covered.
Finally, we only searched for systematic reviews rather than pri-
mary studies to assess the frequency of these conditions. We are 
aware of large- scale analyses of the frequency of important conditions 
such as anemia,51 pregnancy- related infection,52 and fistula,53 which 
provide robust estimates for these conditions. We chose to focus, 
however, on systematic reviews that use standardized methods to 
aggregate existing data.
In conclusion, this review highlights both the existence of sub-
stantial maternal morbidity—spanning the time before and beyond 
childbirth—and major remaining gaps in the availability of systematic 
reviews for some maternal morbidities. Future systematic reviews 
should improve their quality standards, including the strict inclusion of 
population- based studies, and improvement of their review methods 
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and their reporting, following available guidelines. With the changing 
burden of poor maternal health across the globe related to the obstet-
ric transition, there is a pressing need to strengthen the evidence base 
for prioritizing action and further research. A central repository where 
results from new systematic reviews, using standardized terminology 
and metrics, can be stored and readily shared would be invaluable in 
tracking this shifting burden and in informing interventions to reduce 
the impact of maternal morbidities on women’s lives.
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